echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > How difficult will the price of medicine be in 2020?

    How difficult will the price of medicine be in 2020?

    • Last Update: 2019-12-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    [pharmaceutical network industry trends] in 2019, under a series of policies, no matter drugs or medical devices, no matter production or circulation terminals, there will be many changes But looking back, we will find that in these intensive policies, the "4 + 7" volume procurement, the expansion of centralized procurement, and the challenge of medical insurance catalog are all "destructive" to pharmaceutical enterprises It is through these policies that the "cabbage price" drugs are forced out From the perspective of the continuous deepening and expansion of the above policies, the drug price in 2020 will not be too good Most of the winning drugs are generally reduced in price At present, for the large-scale procurement which has a huge impact on the pharmaceutical industry, it is in full swing nationwide For example, as a national pilot, Jiangxi Province has officially announced the volume procurement plan, and it is rumoured in the industry that it will focus on 52 varieties with large consumption and high amount The special procurement of Hebei two diseases and Hunan antibacterial drugs has officially opened the curtain In addition, provincial-level linkage is also a frequent pattern: Tianjin price linkage requires filling in the national online price, while Jiangsu price linkage only excludes Fujian, which is also controversial At the level of prefecture level cities, Wuxi, Hubei, Wuhan, Puyang, Hebei, Handan, Fujian, Putian, Jinan, Shandong and other places may issue plans or officially launch projects It is appropriate to use the word "storm sweeping" In the near future, nine departments including Jiangsu Medical Insurance Bureau jointly issued the implementation plan of Jiangsu Province to promote the implementation of pilot drug centralized procurement and use and expand the regional scope, which made it clear that the results of national pilot expansion and various supporting policies should be fully implemented before December 31 of this year It is estimated that the average price of 25 drugs selected in this round of procurement will be reduced by 59% after landing in Jiangsu, saving 2.6 billion yuan annually It can be predicted from the above that, with the deepening of health care reform, there may be a large number of drugs going on the road of price reduction next year In fact, in addition to the price of bid winning drugs, the price of bid winning drugs has been falling For example, on December 16, the website of Hainan public resources trading service center issued the notice on publicizing the price reduction of the non selected varieties in the expansion of centralized drug procurement, which indicated that the price of the varieties without objection would be reduced after the end of the publicity period, and the varieties without price reduction would be removed from the network After sorting out, 149 out of 235 products that need to be cut in gradient price have chosen to do so The highest drop was that of tenofovir dipivoxil fumarate tablets (300mg, 30 tablets / bottle), which reached 97.5% In addition, in addition to the substantial price reduction of 25 drugs selected in the centralized procurement in Hainan Province, drugs with the same generic name (including dosage form) and the same specification that have been purchased in the centralized procurement service platform of Hainan Province and have not been selected should also be applied for lowering the online price in Hainan according to the national low price On December 17, Jilin Province pharmaceutical machinery procurement service platform also publicized a notice on the results of price reduction of selected and non selected drugs in Jilin Province, which was organized by the state for centralized drug procurement and use pilot area expansion Among them, in addition to 17 winning enterprises involved in 28 batches of drugs have given low prices, 246 batches of unsuccessful drugs have also given prices after the price reduction Conclusion: the future of the pharmaceutical industry is very good, but today it's very heartfelt In 2020, with the joint procurement of evaluated varieties, centralized procurement at the provincial level and group procurement, and further development of drug supply side increment and stock management, it is bound to be more and more difficult for enterprises to maintain prices At this time, medical people should have the mentality of accepting difficulties, coping with difficulties, and even more ways to overcome difficulties! We should try our best to survive first After all, "living" is more important than anything  
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.